A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
Phase 2 Study of Linvoseltamab in Patients With Smoldering Multiple Myeloma at High Risk of Progression to Multiple Myeloma
Sponsor: Regeneron Pharmaceuticals
A PHASE2 clinical study on Smoldering Multiple Myeloma (SMM), this trial is ongoing. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 14 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE2
▶ Show 9 earlier versions
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2023 — Feb 2024 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Badalona, Spain , Barcelona, Spain , El Palmar, Spain , Gijón, Spain , Granada, Spain , Madrid, Spain , Palma Mallorca, Spain , Pamplona, Spain , Pozuelo de Alarcón, Spain , Salamanca, Spain and 3 more locations